This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Plasma cell disorders
Estimated annual incidence
Premalignant condition caused by primary genetic events (e.g., chromosomal translocation, hyperdiploidy, or monosomy)2
- 5% of the population over the age of 503
- MGUS progresses to MM at a rate of 1% per year3
Asymptomatic heterogeneous state between MGUS and MM3
- Compared to MGUS, SMM is 10 times more likely to progress to MM over the first 5 years3
- Patients with high-risk SMM have a 50% risk of progression to MM within 2 years3
Symptomatic* malignant condition caused by secondary genetic events (e.g., acquired chromosomal gains, deletions, translocations, and amplifications)2
- Individuals with pre-existing MGUS are 9x more likely to develop AL amyloidosis5
- End organ damage is driven by amyloid deposits rather than malignant plasma cells5
- AL amyloidosis vs MM
- Differential diagnosis: AL amyloidosis
*Including biomarkers predicting 80% progression to a symptomatic state within 2 years.
AL, amyloid light chain; MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; SMM, smoldering multiple myeloma.
1. Visram A, et al. Hematology Am Soc Hematol Educ Program. 2021;2021(1):673-681. 2. Ho M, et al. Leukemia. 2020;34(12):3111-3125. 3. Rajkumar SV, et al. Blood Cancer J. 2022;12(9):129. 4. SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. Accessed February 20, 2026. http://seer.cancer.gov/statfacts/html/mulmy.html. 5. Merlini G, et al. Nat Rev Dis Primers. 2018: 4(1):38.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.